[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-cancers":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,74,104,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100568241","phase-1-a-study-of-rec-1245-in-participants-with-unresectable-locally-advanced-or-metastatic-cancer-100568241",false,"NCT06678659","A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","A Phase 1 \u002F 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","DAHLIA","Inclusion Criteria:\n\n* Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed \u002F refractory lymphoma\n* Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.\n* Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.\n* Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 \u002F Lugano criteria and documented by computed tomography (CT) and \u002F or magnetic resonance imaging (MRI)\n\nExclusion Criteria:\n\n* Received treatment with another RBM39 degrader\n* Clinically significant gastrointestinal (GI) or GI malabsorption","ALL","12 Years",{"count":20,"type":21},170,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.",[28,29,30,31],"Unresectable","Locally Advanced","Metastatic Cancers","Relapsed\u002FRefractory Lymphomas",[33,34,35,30],"RBM39","Cancer","Refractory Lymphomas","RECRUITING","2026-05-06",{"date":39,"type":40},"2026-05-08","ACTUAL",{"date":42,"type":40},"2024-11-21",{"date":44,"type":21},"2028-10-30",{"name":46,"class":47},"Recursion Pharmaceuticals Inc.","INDUSTRY",6,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100522676","phase-2-combination-therapy-for-cancer-related-fatigue-in-patients-with-metastatic-cancers-100522676","NCT06085716","Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers","Inclusion Criteria:\n\n1. Be advanced cancer patients or s or have a history of advanced cancer, having fatigue with severity of ≥ 4\u002F10, on a 0-10 scale (Edmonton Symptom Assessment Scale), and presence of fatigue for at least 2 weeks.\n2. Have no clinical evidence of cognitive failure as evidenced by treating clinician assessment at screening (Memorial Delirium Assessment Scale of less than 13\u002F30).\n3. Be aged 18 years or older.\n4. Be willing to complete in-person or with research staff, and able to complete Psychoeducational intervention either in person or virtually within Texas.\n5. Have a hemoglobin level of ≥10 g\u002FdL within 2 weeks of enrollment.\n6. Be able to understand the description of the study and sign a written informed consent.\n7. Have a ECOG performance status score of 0 to 2; and\n8. Be seen at an outpatient clinic at MD Anderson Cancer Center's (MDA) main campus or its Houston Area Locations (HALs)\n9. Able to read, write and speak English\n\nExclusion Criteria:\n\n1. Have a major contraindication to placebo (e.g., allergy or hypersensitivity to study medications or their constituents), or conditions making adherence difficult as determined by the attending physician.\n2. Be unable to complete the baseline assessment forms or to understand the recommendations for participation in the study.\n3. Be pregnant (as documented in chart) or become pregnant while on study.","18 Years",{"count":57,"type":21},240,[25,59],"PHASE3","To find out if combining psychoeducational interventions (such as education, counseling, and self-managed therapies) with an open-label placebo can help to improve your quality of life better than either the psychoeducational interventions or the placebo alone.",[30,62],"Fatigue","2026-04-29",{"date":65,"type":40},"2026-05-05",{"date":67,"type":40},"2024-02-16",{"date":69,"type":21},"2029-08-31",{"name":71,"class":72},"M.D. Anderson Cancer Center","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100611087","e-motion--promoting-emotion-regulation-in-chronic-cancer-100611087","NCT07236021","e-Motion : Promoting Emotion Regulation in Chronic Cancer","Promoting Emotion Regulation in Patients Living With Chronic Cancer : A Pilot Feasibility, Acceptability and Tolerability Study (e-Motion Project)","Inclusion Criteria:\n\n* Having received a diagnosis of chronic cancer (metastatic breast cancer, metastatic melanoma, metastatic colorectal, metastatic ovarian, metastatic uterine, metastatic endometrial, metastatic prostate, metastatic bladder, metastatic kidney or metastatic testicular cancer, symptomatic multiple myeloma, metastatic non-small cell lung, metastatic mesothelioma or metastatic thymoma) in the past 12 months,\n* Having completed at least one active treatment session (e.g., chemotherapy, surgery, radiotherapy, immunotherapy, target therapy).\n\nExclusion Criteria:\n\n* Having less than one year of life expectancy\n* Having more than one treatment line (for triple negative breast cancer, melanoma, gynecological cancer, colorectal cancer, bladder cancer, kidney cancer, non-small cell lung, mesothelioma and thymoma) or two treatment lines (for other breast cancers and testicular cancer) or three treatment lines (for prostate cancer and multiple myeloma),\n* Having a diagnosis of oligometastatic cancer,\n* Age \\\u003C 18 years,\n* Non-fluency in French,\n* Inability to follow the online intervention,\n* Severe cognitive impairment, and severe and\u002For acute psychiatric disorder.",{"count":82,"type":21},30,[84],"NA","The present study aimed to pilot evaluate two interventions: a Guided Self-Help Intervention alone, and a combined Group and Guided Self-Help Intervention, designed to support individuals living with chronic cancer and recently diagnosed. The primary aim of this pilot study is to assess the feasibility, acceptability and tolerability of the interventions. The secondary aim of the pilot study is to assess the interventions preliminary efficacy and differences on psychological symptoms.",[30,87],"Myeloma Multiple",[89,90,91,92,93,94],"Advanced cancer","Cognitive Behavioral Therapy (CBT)","Emotional regulation","Ecological Momentary Assessment (EMA)","Hypnosis","Psychotherapy Group","2025-11-20",{"date":97,"type":40},"2025-11-21",{"date":95,"type":40},{"date":100,"type":21},"2026-12-31",{"name":102,"class":72},"Université Libre de Bruxelles",2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":73},"100221093","personalized-oncogenomics-pog-program-of-british-columbia-100221093","NCT02155621","Personalized Oncogenomics (POG) Program of British Columbia","Personalized OncoGenomics (POG) Program of British Columbia: Connecting Cancer Genomics to Cancer Care","Inclusion criteria:\n\n1. Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses.\n2. Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR if there is adequate archival material available, either fresh frozen or FFPE (if specimen is thought to be adequate) that is taken after the most recent chemo or radiation. Ideally this sample should have been collected within 16 weeks of the date of consent. If archival tissue is not adequate and if a biopsy is not feasible or deemed medically safe by the investigators the patient would become ineligible.\n3. Patients must understand and agree to provide a blood test (or other sample of normal DNA) for germline genomic analysis.\n4. ECOG PS 0 or 1.\n5. Age \\>\u002F= 18 years.\n6. Estimated life expectancy \\>\u002F= 6 months and high likelihood of being clinically fit for a therapeutic clinical trial in 3-6 months.\n7. Measurable disease with RECIST v1.1 (or updated version).\n8. Adequate organ function.\n9. Patients must clearly understand that this data may be used to help guide treatment recommendations, including the avoidance of some therapeutic agents or the suggestion to use standard cytotoxic chemotherapy agents.\n10. Willingness to have their de-identified genomic and clinical data shared with national and international research collaborators and data sharing platforms (as detailed in the consent form).\n11. Willingness to be contacted for future studies based on the data that is generated by participation in POG; included in this is the anticipation that patient would be fit or a candidate for clinical trials.\n\nExclusion criteria:\n\n1. Unable or unwilling to consent to the above tissue and blood requirements.\n2. Significant medical condition that in the opinion of the treating or consenting oncologist and\u002For the POG central office review team renders the subject not suitable for participation. This includes the likelihood that a subject would be suitable for a clinical trial within 12 weeks after POG biopsy.\n3. Unwilling or unable to provide treatment and outcome follow up information to the BC Cancer or affiliated investigators.\n4. Unwilling to receive medically actionable findings (germline and\u002For somatic).","85 Years",{"count":113,"type":21},5000,[84],"The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer \"drivers\" and corresponding drugs that may inhibit these pathways.",[30,117,118],"Advanced Cancers","Cancers That Cannot be Treated With Curative Intent",[120,121,122,123],"cancer genomics","precision medicine","metastatic cancer","clinical decision-making","2025-09-17",{"date":126,"type":40},"2025-09-22",{"date":128,"type":4},"2014-07",{"date":130,"type":21},"2026-03",{"name":132,"class":72},"British Columbia Cancer Agency",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":144,"phases":4,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":73},"100587555","assessing-systemic-treatment-and-ctdna-monitoring-efficacy-in-metastatic-cancer-patients-using-k4care-testing-100587555","NCT06929910","Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.","Evaluation of Systemic Therapy and the Effectiveness of Circulating Tumor DNA (ctDNA) Assays in Monitoring Treatment Response in Patients With Metastatic Cancer Undergoing K4Care Testing","GS_ZKM","Inclusion Criteria:\n\n* Pathological and imaging confirmation of metastatic or progressive stage IV cancer.\n* Consent to the use of their clinical data.\n* Diagnosis of one of the following common solid tumor types: lung, colorectal, breast, gastric, or cancer of unknown primary origin.\n* Prior K4Care testing to identify tumor tissue (FFPE) mutations and consent to the use of their sequencing data.\n\nExclusion Criteria:\n\n* Refusal to participate in the study.\n* Absence of prior K4Care testing.\n* Diagnosis of early-stage cancer or hematologic malignancy.\n* Refusal to provide clinical information or blood samples.",{"count":142,"type":21},200,"12 Months","OBSERVATIONAL","The goal of this observational study is to investigate the real-world treatment landscape of patients with metastatic cancer and determine the role of ctDNA in monitoring treatment response in patients with metastatic cancer who have undergone K4Care testing",[30],[148,122],"ctDNA","2025-07-12",{"date":151,"type":40},"2025-07-16",{"date":153,"type":40},"2025-04-09",{"date":155,"type":21},"2027-06-30",{"name":157,"class":47},"Gene Solutions"]